Brielle Benyon

Brielle Benyon

Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.

Follow Brielle on Twitter @Brielle_Benyon.

Articles by Brielle Benyon

Many patients with cancer choose to use homeopathic therapies either in addition to, or in lieu of traditional treatments. However, since these agents don’t go through the same FDA approval process as typical drugs, patients may be subject to harmful effects.

Women with presumed uterine growths known as fibroids who underwent laparoscopic power morcellation (LPM) have higher rates of uterine cancer recurrence and worse outcomes compared to those who got manual or no morcellation, according to a recent release published by the Food and Drug Administration.

When it comes to advancements in treating blood cancers, 2017 was a particularly exciting year, with well over a dozen new therapies or indications approved by the Food and Drug Administration (FDA). The Leukemia & Lymphoma Society has played a role in at least 10 of these new drugs or medication uses at some point throughout their development and approval process.

Hospital readmissions soon after discharge can be costly and detrimental to patient care, but according to a recent study conducted at the Cleveland Clinic and presented at the 2017 American Society of Hematology’s Annual Meeting and Exposition, creating an interdisciplinary team to work with patients can help.